Bioinformatics modernization and the critical path to improved benefit-risk assessment of drugs

Drug Information Journal

Volumn 42, Issue 3, 2008, Pages 273-279

  Oliva, Armando ^a,c   Levin, Randy ^a   Behrman, Rachel ^a   Woodcock, Janet ^b  

^a Office of Critical Path Programs

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NONE   (United States)

Author keywords

Benefit risk assessment; Bioinformatics; Critical path; FDA; Information management

Indexed keywords

ACCESS TO INFORMATION; BIOINFORMATICS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 44649114575     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150804200309     Document Type: Review

References (5)

1. Lacroix Z, Critchlow T. Bioinformatics: Managing Scientific Data. San Francisco: Morgan Kaufman; 2003.
2. See http://www.fda.gov/oc/initiatives/criticalpath/.
3. Critical Path Opportunities List and Report, March 2006. Available at: http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf.
4. See http://www.hhs.gov/healthit/.
5. Critical Path Opportunities List and Report, March 2006, Topic 3: Harnessing Bioinformatics, p. R-15. Available at: http://www.fda.gov/oc/ initiatives/criticalpath/reports/opp_report.pdf.